Introduction {#s1}
============

Breast cancer is the most common type of cancer in women, excluding a few minor skin cancers \[[@R01]\]. The 2013 statistics show that the lifetime probability and the risk of developing breast cancer is 12.29%, or one in every eight women \[[@R02]\]. Centers for Disease Control and Prevention (CDC) data from 2014 in the United States showed 239,109 cases of breast cancer diagnoses within the year \[[@R01]\], while in 2012, data showed 1.7 million diagnoses of breast cancer worldwide \[[@R03]\]. Breast cancer specifically is the most frequently diagnosed cancer and the leading cause of cancer death among women; female breast cancer accounts for 23% of total cancer cases and 14% of deaths by cancer \[[@R03]\]. In 2000, the resulting mortality of the cancer included roughly 375,000 deaths \[[@R04]\].

Breast cancer develops most commonly in women that are 50 years of age or older \[[@R05]\]. A majority of studies are conducted with sample subjects from 50 years and older to study breast cancer overall \[[@R06]\]. Women between the ages of 50 and 74 are recommended to get screening mammograms every 2 years \[[@R07]\], so that the cancer can be detected at an early stage. Early intervention resulted in a decrease in the mortality rate among the older age group of women \[[@R08]\]. There are far less cases of breast cancer in women under 40. The percent of possible development of breast cancer at the age of 30 is 0.44%, or 1 in 228, which is lower than the percentage of any older age group \[[@R04]\]. Breast cancer does not follow more commonly observed linear relationships between incidence and age \[[@R9]\], suggesting a complex role of various risk factors in causing early development. Risk factors for developing cancer at an earlier age may include both internal and external hormonal factors: age at first menarche, age at menopause, age of first pregnancy \[[@R10]\]. Breast cancer in younger women can possibly be observed, on average, as diagnosed at further advanced stages due to factors such as delayed presentation, unfavorable tumor characteristics, genetic mutations, and/or family history of breast cancer \[[@R11]\].

Since there is not a clear guidance in the screening of early detection of breast cancer in younger age group women compared to established guidelines for the older women, the study was designed to look at the incidence and behavior of breast cancer at the time of the diagnosis in younger women.

Hypothesis {#s1a}
----------

Breast cancer in younger women (\< 40 years old) will be diagnosed at a higher grade than for older women (≥ 40).

Materials and Methods {#s2}
=====================

Data source {#s2a}
-----------

Cases for breast cancer patients were collected from the public National Cancer Institute (NCI) Surveillance, Epidemiology and End Results (SEER) Program database. Collaborative Institutional Training Initiative (CITI Program) Training was completed for access to the SEER data, which was provided for the principal investigator by a biostatistician from Jersey Shore University Medical Center. The database provides access to demography, tumor behavior and histology. The data are de-identified and anonymous, with the database being the largest repository of cancer cases in the United States. The SEER registries house millions of cases of cancer patients all across the United States: San Francisco-Oakland, Connecticut, Metropolitan Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Metropolitan Atlanta, Alaska, San Jose-Monterey, Los Angeles, Rural Georgia, Greater California, Kentucky, Louisiana, New Jersey and Greater Georgia.

Inclusion and exclusion criteria {#s2b}
--------------------------------

Cases were extracted from the SEER database for the sampling time frame between 2004 and 2014. All female patients who were diagnosed with breast cancer and confirmed with histology and/or cytology were included in the study. The patient's demographic characteristics including age, race and marital status at the time of diagnosis were collected. Other variables included in the study were tumor characteristics: size, location, histology, extension, metastasis, receptor status, stage and grades of the tumor (high grade: grades III and IV; low grade: grades I and II). All male breast cancer cases were excluded from the study. Breast cancer cases diagnosed at autopsy were also excluded. Variables were excluded from the overall dataset for more accurate analysis, including variables in accordance with old coding systems, variables with too many missing (NA) code values and variables that proved irrelevant to the purpose of the study. Listwise deletion was then performed for the remaining variables to delete values that were unknown, inapplicable, or unspecified. These values were set as missing values and further deleted to create a clean dataset. Any variables with only missing values that remained from the selection process were removed from the dataset to prevent data corruption. Duplicate cases were then dropped from the dataset to prevent inaccurate analysis ([Fig. 1](#F1){ref-type="fig"}).

![Inclusion and Exclusion Criteria.](wjon-11-088-g001){#F1}

Statistical analysis {#s2c}
--------------------

The data set was divided into a younger age group (age \< 40 years old) and older age group (≥ 40 years old). The two groups were compared on patients' characteristics and tumor characteristics. The summary statistics were obtained and presented the following values for both age groups for the continuous variables: mean, standard deviation (SD), median and interquartile range (IQR; first and third quartiles). The Student's *t*-test was used for each continuous variable. The categorical variables were compared between the two groups using Pearson's Chi-squared (χ^2^) test or Fisher's exact test. In order to eliminate confounding variables, multivariate logistic regression analysis was performed to examine relationships between high-grade tumors and age of the patient at the time of diagnosis. The statistical coding language R was used with Rstudio, its integrated development environment (IDE), as well as packages "dplyr", "stats" and "psych" within the IDE for efficiency in data manipulation and statistical functionality when analyzing the data. All P-values are two-sided and the values \< 0.05 are considered as statistically significant.

The primary outcome of the study was the stage of the tumor at the time of diagnosis. Secondary outcomes were tumor receptors' status and presence of metastasis.

Results {#s3}
=======

A total of 810,835 cases were reported in the SEER registry from 2004 to 2014. Out of those, 599,782 cases satisfied the inclusion criteria. A majority, 571,539 (95.29%) of patients who were diagnosed with breast cancer were 40 years old or above (older group) and the remaining 28,243 (4.71%) belonged to the younger group. The mean (SD) age of the younger group was 34.89 (3.80) years and the mean (SD) age of the older group was 62.158 (12.51). When comparing the marital status, a higher proportion of patients in the younger group were single compared to the older group (28.80% versus 13.39%, P \< 0.001). Regarding race, there was a higher percentage of black women with breast cancer cases identified in the younger group compared to the older group (15.32% versus 10.26%, P \< 0.001). The most common primary site (the site that cancer originated) between both groups was the upper-outer quadrant of the breast, split almost evenly between cases involving either the right or left breast, with almost all cases having diagnoses confirmed with positive histology ([Table 1](#T1){ref-type="table"}).

###### Demographic and Clinical Characteristics Comparison of Two Groups

  Variables                                                                             Younger group (0 - 39), n = 28,243 (4.709%)   Older group (40+), n = 571,539 (95.291%)   P-value
  ------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------ ----------
  Age at diagnosis                                                                                                                                                               \< 0.001
    Mean (SD)                                                                           34.889 (3.81)                                 62.158 (12.51)                             
    Median (IQR)                                                                        36 (33 - 38)                                  61 (52 - 71)                               
  Marital status, n (%)                                                                                                                                                          \< 0.001
    Single (never married)                                                              8,133 (28.80)                                 76,542 (13.39)                             
    Married (including common law)                                                      17,730 (62.78)                                331,938 (58.08)                            
    Separated                                                                           433 (1.53)                                    5,703 (1.00)                               
    Divorced                                                                            1,755 (6.21)                                  64,914 (11.36)                             
    Widowed                                                                             130 (0.46)                                    91,723 (16.05)                             
    Unmarried/domestic partner                                                          62 (0.22)                                     719 (0.13)                                 
  Race, n (%)                                                                                                                                                                    \< 0.001
    White                                                                               20,345 (72.04)                                463,663 (81.13)                            
    Black                                                                               4,328 (15.32)                                 58,330 (10.21)                             
    American Indian/Alaska Native                                                       185 (0.66)                                    2,784 (0.49)                               
    Asian or Pacific Islander                                                           3,385 (11.99)                                 46,762 (8.18)                              
  Insurance status, n (%)                                                                                                                                                        \< 0.001
    Uninsured                                                                           679 (2.40)                                    6,057 (1.06)                               
    Any Medicaid                                                                        3,375 (11.95)                                 43,192 (7.56)                              
    Insured                                                                             14,467 (51.22)                                318,414 (55.71)                            
    Insured/no specifics                                                                1,965 (6.96)                                  60,277 (10.55)                             
    Insurance status unknown                                                            252 (0.89)                                    5,137 (0.90)                               
    Undocumented                                                                        7,505 (26.57)                                 138,462 (24.23)                            
  Primary site, n (%)                                                                                                                                                            \< 0.001
    Nipple                                                                              79 (0.28)                                     2,746 (0.48)                               
    Central portion of breast                                                           1,130 (4.00)                                  31,136 (5.45)                              
    Upper-inner quadrant of breast                                                      3,104 (10.99)                                 65,068 (11.38)                             
    Lower-inner quadrant of breast                                                      1,437 (5.09)                                  33,857 (5.92)                              
    Upper-outer quadrant of breast                                                      9,516 (33.69)                                 195,041 (34.13)                            
    Lower-outer quadrant of breast                                                      2,254 (7.98)                                  41,689 (7.29)                              
    Axillary tail of breast                                                             228 (0.81)                                    2,967 (0.52)                               
    Overlapping lesion of breast                                                        6,206 (21.97)                                 128,795 (22.54)                            
    Breast, NOS                                                                         4,289 (15.19)                                 70,240 (12.29)                             
  Diagnosis confirmation, n (%)                                                                                                                                                  0.008
    Positive histology                                                                  28,175 (99.76)                                570,584 (99.83)                            
    Positive cytology                                                                   63 (0.22)                                     809 (0.14)                                 
    Positive histology and positive immunophenotyping and/or positive genetic studies   0 (0.00)                                      2 (0.00)                                   
    Positive microscopic confirmation, method not specified                             5 (0.02)                                      144 (0.03)                                 

NOS: not otherwise specified; SD: standard deviation; IQR: interquartile range.

When comparing the outcomes between the two groups, younger group women displayed higher percentages of tumors in size ranges 2.1 - 5.0 cm and 5.1 - 10.0 cm when compared to the older group (42.65% vs. 28.73% and 11.61% vs. 5.70%, P \< 0.001), respectively ([Table 2](#T2){ref-type="table"}). A higher percentage of cases from the younger group had regional as well as distant metastasis when compared to older group (40.76% vs. 24.93% and 6.83% vs. 3.81%, P \< 0.001). Similarly, the younger group also had higher percentages of poorly differentiated cancerous cells when compared to the older group (55.88% vs. 32.85%, P \< 0.001). Younger women displayed a higher percentage of invasive carcinoma at their primary site compared to older women (91.45% vs. 85.23%, P \< 0.001). Regarding receptor assay analysis, estrogen receptor (ER) assay, progesterone receptor (PR) assay and human epidermal growth factor receptor 2 (HER2) protein analysis, triple negative receptors assay ER(-), PR(-) and HER2(-) cases were found to be almost double in the younger group compared to the older group (7.83% vs. 4.31%, P \< 0.01) ([Table 2](#T2){ref-type="table"}). Analysis of stage based on TNM classification (AJCC seventh edition) displayed younger women having approximately double the percentage of stage 4 cancers compared to older women (2.42% vs. 1.48, P \< 0.001) ([Table 3](#T3){ref-type="table"}).

###### Tumor Characteristics Between the Two Groups

  Variables                                                                                Younger group (0 - 39), n = 28,243 (4.709%)   Older group (40+), n = 571,539 (95.291%)   P-value
  ---------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------ ----------
  Tumor size, n (%)                                                                                                                                                                 \< 0.001
    0.1 - 2.0 cm                                                                           12,121 (42.92)                                362,102 (63.36)                            
    2.1 - 5.0 cm                                                                           12,045 (42.65)                                164,218 (28.73)                            
    5.1 - 10.0 cm                                                                          3,278 (11.61)                                 32,596 (5.70)                              
    10.1 cm+                                                                               419 (1.48)                                    4,348 (0.76)                               
    Diagnosis confirmed but size undefined                                                 380 (1.35)                                    8,275 (1.45)                               
  Grade, n (%)                                                                                                                                                                      \< 0.001
    Grade I: well differentiated; differentiated, NOS                                      2,249 (7.96)                                  123,875 (21.67)                            
    Grade II: moderately differentiated; intermediate differentiation                      9,560 (33.85)                                 247,788 (43.36)                            
    Grade III: poorly differentiated; differentiated                                       15,783 (55.88)                                187,737 (32.85)                            
    Grade IV: undifferentiated; anaplastic                                                 651 (2.31)                                    12,139 (2.12)                              
  Immunohistochemistry (IHC) of regional lymph nodes, n (%)                                                                                                                         \< 0.001
    Nodes clinically negative, not examined pathologically                                 9,560 (33.85)                                 275,155 (48.14)                            
    Negative on routine H and E, IHC studies done, negative for tumor                      5,233 (18.53)                                 134,288 (23.50)                            
    Negative on routine H and E, IHC studies done, positive for ITCs                       349 (1.24)                                    6,020 (1.05)                               
    Negative on routine H and E, IHC tumor positive, metastases not stated                 56 (0.20)                                     1,115 (0.20)                               
    Not applicable                                                                         13,045 (46.19)                                154,961 (27.11)                            
  Molecular (MOL) studies of regional lymph nodes, n (%)                                                                                                                            \< 0.001
    Nodes clinically negative, not examined pathologically                                 14,212 (50.32)                                392,877 (68.74)                            
    Negative on routine H and E, RT-PCR MOL studies done, negative for tumor               954 (3.38)                                    23,175 (4.06)                              
    Negative on routine H and E, RT-PCR MOL studies done, positive for tumor               32 (0.11)                                     526 (0.09)                                 
    Not applicable                                                                         13,045 (46.19)                                154,961 (27.11)                            
  Metastasis at diagnosis, n (%)                                                                                                                                                    \< 0.001
    No distant metastasis                                                                  26,949 (95.42)                                555,563 (97.21)                            
    Microscopic, \< 0.2 mm without symptoms or signs of metastasis                         2 (0.01)                                      27 (0.01)                                  
    Stated as M0(i+) with no other information on distant metastasis                       1 (0.00)                                      4 (0.00)                                   
    Unilateral or bilateral axillary or cervical nodes                                     122 (0.43)                                    1,148 (0.20)                               
    Distant metastasis except distant lymph node(s); Carcinomatosis                        415 (1.47)                                    4,848 (0.85)                               
    Skin over: axilla, contralateral (opposite) breast, sternum, upper abdomen             13 (0.05)                                     166 (0.03)                                 
    Adrenal bone, lung ovary satellite nodule, or opposite breast metastasis               512 (1.81)                                    6,735 (1.18)                               
    Distant lymph nodes; carcinomatosis                                                    196 (0.69)                                    2,506 (0.44)                               
    Distant metastasis, NOS                                                                33 (0.12)                                     542 (0.10)                                 
  Behavior, n (%)                                                                                                                                                                   \< 0.001
    Carcinoma *in situ*; intraepithelial; non-infiltrating; noninvasive                    2,413 (8.54)                                  84,397 (14.77)                             
    Malignant, primary site (invasive)                                                     25,830 (91.46)                                487,142 (85.23)                            
  Simplified stage, n (%)                                                                                                                                                           \< 0.001
    *In situ*                                                                              2,413 (8.54)                                  84,397 (14.77)                             
    Localized                                                                              12,388 (43.86)                                322,914 (56.50)                            
    Regional                                                                               11,512 (40.76)                                142,482 (24.93)                            
    Distant                                                                                1,930 (6.83)                                  21,746 (3.81)                              
  Size of tumor-invasive component, n (%)                                                                                                                                           \< 0.001
    Entire tumor reported as invasive                                                      8,153 (28.87)                                 159,696 (27.94)                            
    Entire tumor reported as *in situ*                                                     2,407 (8.52)                                  84,191 (14.73)                             
    Invasive and *in situ* components present                                              10,788 (38.20)                                217,644 (38.08)                            
    Invasive/*in situ* components present, *in situ* described as minimal (\< 25%)         2,376 (8.41)                                  52,107 (9.12)                              
    Invasive/*in situ* components present, in situ described as extensive (\> 25%)         1,026 (3.63)                                  13,855 (2.42)                              
    Invasive/*in situ* components present, proportions in situ and invasive unknown        1,866 (6.61)                                  30,050 (5.26)                              
    Unknown if invasive/*in situ* components present, unknown if tumor "pure" or "mixed"   1,627 (5.76)                                  13,996 (2.45)                              
  Estrogen receptor (ER) status, n (%)                                                                                                                                              \< 0.001
    Positive                                                                               18,676 (66.13)                                446,374 (78.10)                            
    Negative                                                                               8,476 (30.01)                                 97,525 (17.06)                             
    Borderline                                                                             53 (0.19)                                     714 (0.13)                                 
    Unknown                                                                                1,038 (3.68)                                  26,926 (4.71)                              
  Progesterone receptor (PR) status, n (%)                                                                                                                                          \< 0.001
    Positive                                                                               16,232 (57.47)                                379,407 (66.38)                            
    Negative                                                                               10,619 (37.60)                                155,506 (27.21)                            
    Borderline                                                                             121 (0.43)                                    2,129 (0.37)                               
    Unknown                                                                                1,271 (4.50)                                  34,497 (6.04)                              
  Human epidermal growth factor receptor 2 (HER2), n (%)                                                                                                                            \< 0.001
    Positive                                                                               2,954 (10.46)                                 32,687 (5.72)                              
    Negative                                                                               8,366 (29.62)                                 193,630 (33.88)                            
    Borderline                                                                             229 (0.81)                                    5,332 (0.93)                               
    Unknown                                                                                1,261 (4.47)                                  44,744 (7.83)                              
    Not 2010+ breast                                                                       15,433 (54.64)                                295,146 (51.64)                            
  Breast subtype, n (%)                                                                                                                                                             \< 0.001
    Her2+/HR+                                                                              2,136 (7.56)                                  22,848 (4.00)                              
    Her2+/HR-                                                                              814 (2.88)                                    9,771 (1.71)                               
    Her2-/HR+                                                                              6,146 (21.76)                                 168,694 (29.52)                            
    Triple negative                                                                        2,212 (7.83)                                  24,654 (4.31)                              
    Unknown                                                                                1,502 (5.32)                                  50,426 (8.82)                              
    Not 2010+ breast                                                                       15,433 (54.64)                                295,146 (51.64)                            
  High grade, n (%)                                                                                                                                                                 \< 0.001
    Higher grade                                                                           16,434 (58.19)                                199,876 (34.97)                            
    Lower grade                                                                            11,809 (41.81)                                371,663 (65.03)                            

NOS: not otherwise specified; ITCs: isolated tumor cells.

###### Adjusted Stage Based on TNM Classification (Seventh Edition)

  Stage, n (%)           Younger group (0 - 39), n = 28,243 (4.709%)   Older group (40+), n = 571,539 (95.291%)   P \< 0.001
  ---------------------- --------------------------------------------- ------------------------------------------ ------------
  0                      1,201 (4.25)                                  44,979 (7.87)                              
  IA                     3,102 (10.98)                                 119,099 (20.84)                            
  IB                     285 (1.01)                                    5,456 (0.95)                               
  IIA                    3,152 (11.16)                                 51,100 (8.94)                              
  IIB                    2,300 (8.14)                                  25,060 (4.38)                              
  III NOS                4 (0.01)                                      14 (0.00)                                  
  IIIA                   1,419 (5.02)                                  13,959 (2.44)                              
  IIIB                   316 (1.12)                                    4,322 (0.76)                               
  IIIC                   498 (1.76)                                    5,741 (1.00)                               
  IV                     683 (2.42)                                    8,464 (1.48)                               
  Not applicable         25 (0.09)                                     171 (0.03)                                 
  Stage unknown          31 (0.11)                                     387 (0.07)                                 
  Undocumented/missing   15,227 (53.91)                                292,787 (51.23)                            

NOS: not otherwise specified.

When the high-grade tumor was assessed in the multivariate logistic regression analysis controlling for race and marital status, the younger age group was significantly associated with a higher percentage of high-grade tumor development. A decrease of 1 year of age related to almost 3% increased risk of a high-grade tumor (odds ratio (OR) 0.97, 95% confidence interval (CI) 0.96 - 0.99, P = 0.001) ([Table 4](#T4){ref-type="table"}).

###### Multivariate Analysis of High-Grade Tumor Using Age Group

  Covariate                          Odds ratio   P-value    95% confidence interval
  ---------------------------------- ------------ ---------- -------------------------
  Race                                                       
    Black                            1.660        \< 0.001   1.63 - 1.69
    American Indian/Alaska Native    1.138        0.001      1.06 - 1.23
    Asian or Pacific Islander        1.074        \< 0.001   1.05 - 1.10
  Marital status                                             
    Married (including common law)   0.973        0.001      0.96 - 0.99
    Separated                        1.057        0.040      1.00 - 1.12
    Divorced                         1.008        0.483      0.99 - 1.03
    Widowed                          1.109        \< 0.001   1.09 - 1.13
    Unmarried/domestic partner       0.853        0.036      0.73 - 0.99
  Age at diagnosis                   0.978        \< 0.001   0.98 - 0.98
  Constant                           2.025        \< 0.001   1.97 - 2.09

White race and single marital status were used as a reference in the analysis.

When the age was further analyzed through multivariate logistic regression to determine the correlation between the age group and the grading of the tumor, it was found that the younger age group has 2.437 higher odds (95% CI 2.38 - 2.50, P \< 0.001) of having a high-grade tumor at the time of diagnosis ([Table 5](#T5){ref-type="table"}).

###### Multivariate Analysis of Age Group With High-Grade Tumor

  Covariate                          Odds ratio   P-value    95% confidence interval
  ---------------------------------- ------------ ---------- -------------------------
  Younger vs older age               2.437        \< 0.001   2.38 - 2.50
  Marital status                                             
    Married (including common law)   0.535        \< 0.001   0.52 - 0.55
    Separated                        0.696        \< 0.001   0.63 - 0.77
    Divorced                         0.267        \< 0.001   0.25 - 0.28
    Widowed                          0.015        \< 0.001   0.01 - 0.02
    Unmarried or domestic partner    0.898        0.422      0.69 - 1.17
  Race                                                       
    Black                            1.318        \< 0.001   1.27 - 1.37
    American Indian/Alaska Native    1.347        \< 0.001   1.16 - 1.57
    Asian or Pacific Islander        1.491        \< 0.001   1.44 - 1.55
  Constant                           0.062        \< 0.001   0.06 - 0.06

High grade: grades III and IV. Low grade (grades I and II), white race and single marital status were used as references in the analysis.

Discussion {#s4}
==========

From the 599,782 SEER cases analyzed in this study, 28,243 cases were diagnosed in women 0 - 39 years of age, making up 4.71% of the total. Evidence demonstrates these younger women being diagnosed with more aggressive tumors and cancerous growths compared to women diagnosed at 40 years of age and older. The qualitative aggressiveness is based upon the younger group having a higher proportion of high-grade diagnoses, as well as higher invasiveness, more distant metastases, the increased likeliness of carcinomatosis and larger tumors.

Incidence of breast cancer in younger women is lower than in older women, increasing as age increases. However, women at risk under 40, under the recommended screening age, can be more prone to aggressive tumors, putting them at higher risk of fatality \[[@R12]\]. A study examining cases from 1989 to 2009 in Galway University Hospital displayed similar results on a smaller scale. The study showed younger women to have significantly higher grade and stage, as well as higher HER2 over-expression \[[@R11]\]. A San Antonio database study revealed younger women to have the worst survival outcome when compared to older women at the same stages of cancer. Analyses showed more positive lymph nodes, larger tumors and negative steroid hormone receptors in younger patients \[[@R13]\]. Younger women with the same advanced stages of breast cancer as older women demonstrated breast cancer to be more fatal. An additional study examining 72,367 SEER database cases from 1973 to 1998 displayed younger women with distant metastasis to have poorer prognosis and a higher likelihood of fatality \[[@R14]\].

When examining breast cancer cases of women in Asia, a study found that women below 35 presented poorer prognostic profiles, including higher-grade tumors and more prevalent nodal involvement \[[@R15]\]. A Singapore-Malaysia hospital database study found that women younger than 50 comprised 51% of diagnosed cases, roughly double the percent under 50 years old in the USA \[[@R16]\]. An additional study of Asian Indian/Pakistani women in the USA from the SEER database presented this group of women to demonstrate more ER/PR negative cases than Caucasians. This group of Indian/Pakistani women also had roughly 10% more cases of women diagnosed at ages less than 40 compared to Caucasians. However, survival outcome was generally similar to that of Caucasians, while that of African American women was worse \[[@R17]\]. Considering African American females showed a higher percentage of breast cancer cases identified in the younger group, a study focusing on African-British women showed black women presenting 21 years younger than white women on average \[[@R18]\]. This suggests an increased risk for this race group in America and Britain.

The most common primary site of breast cancer being the upper-outer quadrant of the breast may be correlated with the greater amount of breast tissue and density in the specific region of the breast \[[@R19]\]. Although this quadrant of the breast is closest to the axillary lymph nodes and cancer may spread to these nodes over time, the original tumor location is not an independent prognostic factor in determining metastasis \[[@R20]\].

There are numerous reports which demonstrate that the major advances in survival documented in young breast cancer patients in the last decade have resulted from advances in treatment as these improvements in overall survival (OS) are documented in screened and unscreened populations. Pathologic complete response to neoadjuvant systemic therapy in high-risk cancers such as triple negative and Her-2 driven cancers appear to be independent of stage I-III, and thus it is likely that the biological behavior of these tumors is dictated by chemosensitivity more than by their stage. Thus, Guo et al \[[@R21]\] in an excellent SEER-based study of breast cancer in young women concluded that screening has contributed little to the improvements in OS in this population. They concluded that even in the screened population of women \> 40 "nearly all of the mortality reduction was caused by treatment advances and NOT screening".

In a similar vein, Anders et al \[[@R22]\] concluded that the increased proportion of aggressive intrinsic tumor subtypes (most of which are high-grade lesions) can account for differences in tumor behavior in young women. They suggested that new targeted chemotherapy and systemic therapy can erase the importance of age as a prognostic factor.

Younger women that develop breast cancer often suffer prolonged psychological and physical issues including menopause-related concerns, weight gain and physical inactivity \[[@R23]\]. This raises concerns to diagnose breast cancer in younger women at earlier stages to decrease prolonged issues and improve survival outcomes.

This study utilizes one of the largest sample sizes, 599,782 cases, analyzed from the SEER database. The age-based analysis of outcome factors indicated younger women to have higher likeliness of being diagnosed at advanced stages of breast cancer as opposed to older women who are more regularly screened. The larger growth may possibly result from a lack of screening guidelines concerning younger women. However, regular screening by digital mammography in women aged 40 - 49 years showed lower specificity. Therefore, the current recommendation for screening in this age group is to individualize patients based on risk factors \[[@R24]\]. Self-breast examinations and physician examinations yielded even lower positive results in women younger than 40 years old \[[@R25], [@R26]\]. As studies involving women below 40 are scarcer, there is less understanding on how to narrow screenings for the likelihood of developing cancer for these individuals. This study validates the results of other studies that younger women with breast cancer are diagnosed with advanced stages of cancer compared to older women \[[@R11], [@R12], [@R14], [@R27]\]. The higher mortality among younger patients who presented with the same stage breast cancer as older women \[[@R13]\] provides an insight and need to create some strategies to identify cancer at an early stage. Despite the mortality rate plateauing in breast cancer in women between the ages of 20 and 29 years since 2005, the incidence of metastatic disease in this age group continues to increase \[[@R26]\]. Removal of acquired risk factors, early detection and timely interventions should be the few steps towards tackling a very difficult problem younger women face.

Limitations {#s4a}
-----------

The study was performed utilizing retrospective data from the SEER database, constituting inherent bias in the study sample. As the cases in the database were de-identified with a set guideline of variables, detailed information regarding individual hormonal factors was not included: age of first menarche, age of first pregnancy, age at menopause. Since no such information was available, consideration of these factors was left out of the study design. As a result of analyzing the database, certain variables were excluded based on consideration of the sample size as well as a lack of information regarding different variables.

Conclusion {#s4b}
----------

Breast cancer is indicated to be diagnosed as more aggressive at higher grades in younger women when compared to diagnoses in older women. Tumors of these cases are often observed to be more invasive at the primary site while having more regional and distant metastases. Additionally, younger cases display larger tumors with more characteristics of poor prognosis.

Future work {#s4c}
-----------

A future study may be conducted with the database that can provide detailed information of the characteristics of younger women. Further studies may also be conducted focusing more on risk for groups of women from different countries living in the USA. This may provide more evidence of risk for specific groups of women that could further narrow developing screening guidelines.
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